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Abstract
Introduction: The aim of this study was to evaluate auditory organ function in relatively young type 1 diabetic patients, with short
duration of the disease and without overt hearing loss. The impact of age, diabetes duration and metabolic control on hearing function was
also analysed.
Material and methods: Thirty-one patients with type 1 diabetes, aged below 45 years (mean 29.1 ± 7.1 years), with diabetes duration of
less than 120 months (mean 54.7 ± 32.5 months), and no evident hearing impairment, were compared to 26 age-matched (30.3 ± 7.8 years,
p = 0.567) healthy volunteers. In all subjects, pure-tone audiometry, transient evoked otoacoustic emissions (TEOAE), and auditory brain-
stem responses (ABR) were performed, after an ENT examination.
Results: In diabetic patients, compared to healthy subjects, the mean hearing threshold in the pure-tone audiometry was significantly
higher at high frequencies, the mean amplitude of TEOAE was lower (7.75 ± 4.43 dB v. 10.00 ± 4.01 dB, p < 0.001), and latency times of
wave V and interval I–V in ABR were longer (5.78 ± 0.25 ms v. 5.69 ± 0.18 ms, p = 0.025 and 4.03 ± 0.20 ms v. 3.95 ± 0.17 ms, p = 0.017
respectively). In the diabetic group, the hearing threshold showed positive linear correlation with age, whereas TEOAE was inversely
correlated with this parameter. In ABR latency, times of wave V and interval I–V were negatively correlated with diabetes duration.
Conclusions: This study confirms the involvement of the auditory organ in type 1 diabetes mellitus. To determine the prognostic and
predictive values of this finding, and methods of possible prevention of hearing loss, further prospective observations are required.
(Pol J Endocrinol 2011; 62 (2): 138–144)
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Streszczenie
Wstęp: Celem badania była ocena funkcji narządu słuchu u relatywnie młodych osób z cukrzycą typu 1, o krótkim czasie trwania choroby
i bez jawnych klinicznie ubytków słuchu. Analizie poddano także wpływ wieku, czasu trwania cukrzycy i jej kontroli metabolicznej na
funkcję słuchu.
Materiał i metody: Trzydzieści jeden osób z cukrzycą typu 1, w wieku poniżej 45 lat (średnio 29,1 ± 7,1 lat), z czasem trwania cukrzycy
poniżej 120 miesięcy (średnio 54,7 ± 32,5 miesięcy), i bez jawnego ubytku słuchu, porównano z dwudziestoma sześcioma zdrowymi
ochotnikami dopasowanymi pod względem wieku (30,3 ± 7,8 lat, p = 0,567). U wszystkich osób, po przeprowadzeniu badania laryngolo-
gicznego, wykonano badanie audiometrii tonalnej progowej, emisji otoakustycznej wywołanej trzaskiem oraz słuchowych potencjałów
wywołanych pnia mózgu.
Wyniki: U osób z cukrzycą średni próg słuchu w audiometrii tonalnej progowej był znamiennie wyższy w wysokich częstotliwościach,
średnia amplituda emisji otoakustycznej była niższa (7,75 ± 4,43 dB v. 10,00 ± 4,01 dB, p < 0,001), także czasy latencji fali V i interwału
I–V w badaniu słuchowych potencjałów wywołanych były dłuższe (odpowiednio 5,78 ± 0,25 ms v. 5,69 ± 0,18 ms, p = 0,025 i 4,03 ± 0,20 ms
v. 3,95 ± 0,17 ms, p = 0,017) w porównaniu z osobami zdrowymi. U osób z cukrzycą próg słuchu wykazywał dodatnią, zaś amplituda
emisji otoakustycznej ujemną korelację liniową z wiekiem. W badaniu słuchowych potencjałów wywołanych czasy latencji fali V i inter-
wału I–V ujemnie korelowały z czasem trwania cukrzycy.
Wnioski: Praca ta potwierdza wpływ cukrzycy typu 1 na funkcję narządu słuchu. Dla oceny wartości prognostycznej uzyskanych wyni-
ków, jak też potencjalnych sposobów zapobiegania uszkodzeniu słuchu w cukrzycy konieczne są dalsze prospektywne badania tego
zjawiska. (Endokrynol Pol 2011; 62 (2): 138–144)
Słowa kluczowe: cukrzyca typu 1, upośledzenie słuchu, audiometria tonalna progowa, emisje otoakustyczne, potencjały wywołane pnia mózgu
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Introduction
Type 1 diabetes is a chronic metabolic disorder charac-
terised by hyperglycaemia resulting from autoimmune
destruction of the beta-cells of the pancreas. An elevat-
ed blood glucose level can lead to dysfunction, damage
and failure of various organs, especially the eyes, kid-
neys, nerves, heart and blood vessels [1]. One of the
lesser known consequences of diabetes is auditory or-
gan dysfunction.
Although there is mounting evidence for a relation-
ship between type 1 diabetes and hearing impairment
[2–15], the awareness of auditory organ involvement in
the course of diabetes is still not widespread among
healthcare providers involved in diabetes care. Altered
hearing function in diabetic patients has been found in
both pure-tone audiometry [2–8] and otoacoustic emis-
sions [9–12], as well as in auditory brainstem responses
[7, 9–11, 13–15].
Pure-tone audiometry is used to determine a hear-
ing threshold, i.e. the softest sound audible to the per-
son being studied. This measure reflects auditory or-
gan function as a whole, both its peripheral and central
parts [16]. An otoacoustic emission (OAE) test is used to
determine the status of the cochlear micromechanics,
especially the function of the outer hair cells (OHC) [17].
Auditory brainstem response audiometry is a neurolog-
ical test used to determine function of the retrocochlear
part of the auditory pathway, up to brainstem level [18].
Since previous studies had examined highly heter-
ogeneous populations, predominantly patients with
long lasting diabetes and often with microvascular dia-
betic complications, we decided to evaluate whether
auditory organ dysfunction exists in relatively young
type 1 diabetic subjects, with a short duration of the dis-
ease, and with no clinically evident hearing impairment.
The secondary objective of our study was to evaluate
the impact of age, duration of diabetes, and metabolic
control on hearing function in type 1 diabetes. Associa-
tions of retinopathy and urinary albumin excretion with
auditory function were also analysed.
To evaluate the whole auditory pathway, with both
its cochlear and retrocochlear parts, the three audiolog-
ical tests described above were performed.
Material and methods
Participants
Inclusion criteria were: to be aged below 45 (to avoid
the impact of presbyacusis), and to have had diabetes
for less than 10 years (for the diabetic group) to exclude
patients with advanced diabetic complications. Exclu-
sion criteria were: clinically overt hearing loss and/or
prolonged exposure to noise and/or a history of ototox-
ic medications. The study group consisted of 31 type 1
diabetic patients (eight female and 23 male), with
a mean age of 29.1 ± 7.1 years (range 18–43), who were
being treated in the diabetic outpatient clinic at the Beta-
Med Medical Centre, Rzeszow, Poland. The control
group consisted of 26 healthy age-matched (30.3 ± 7.8,
range 19–43, p = 0.567) volunteers. They included hos-
pital staff, students and drug company representatives
(19 female and seven male).
In all but one of the diabetic subjects, an ophthal-
moscopic eye fundus evaluation was performed by an
ophthalmologist.
The metabolic control of diabetes was determined
by HbA1C measurement, and the presence of microal-
buminuria was determined by the albumin concentra-
tion and albumin/creatinine ratio assessment from
a morning sample of urine. Both measurements were
performed using a DCA 2000® + analyser (Bayer Cor-
poration, Elkhart, IN, USA) using the monoclonal anti-
body method.
Among the diabetic group, three patients had early
background retinopathy, one had urinary albumin ex-
cretion in the microalbuminuric range, but none had
clinically overt diabetic neuropathy.
Audiological tests
In all subjects, before the audiological tests, a detailed
ear examination by a single otorhinolaryngologist was
performed to exclude abnormalities in the external and
middle ear. Then pure-tone audiometry, transient
evoked otoacoustic emissions and auditory brainstem
responses were assessed. All evaluations were per-
formed in the Department of Otorhinolaryngology at
the Provincial Specialist Hospital in Rzeszow, Poland.
Pure-tone audiometry was performed in a sound-
proof booth, using a Madsen OB822 audiometer (GN
Otometrics, Taastrup, Denmark) with Telephonics TDH
39 earphones. The air conduction was measured at the
frequency range 125–12,000 Hz, and the bone conduc-
tion was measured at frequencies 250–6,000 Hz. The
initial stimulus was 10 dB HL (hearing level). Then the
level was increased in 5-dB HL steps. Mild hearing im-
pairment was recognised at hearing thresholds above
20 dB in at least one frequency, and moderate hearing
impairment was recognised at hearing thresholds above
40 dB.
Transient evoked otoacoustic emissions were obtained
using a Scout Sport 580-OAE SP6 Analyser (Bio-logic
Systems Corp., Mundelein, IL, USA) with a ‘non-linear’
click stimulus of 80 µs duration, a repetition rate of 50 Hz,
and an intensity of ~80 dB. The results were presented
in dB as an average for band range 1.2–3.5 kHz, and
also for particular frequencies of TEOAE spectrum:
1, 1.5, 2, 3 and 4 kHz. A mean TEOAE amplitude below
140
Auditory organ involvement in type 1 diabetes Mariusz Dąbrowski et al.
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
6 dB at band range 1.2–3.5 kHz was considered as a lack
of otoacoustic emission.
Auditory brainstem responses were evaluated using
a Centor-C analyser (Racia-Alvar, Paris, France) with click
stimulus of 100 µs duration, a repetition rate of 19.1 Hz,
an intensity of 70 dB, and a contralateral ear masking of
-30 dB. Electrodes were placed on the forehead (posi-
tive), the ipsilateral mastoid (negative), and chin
(ground). The latency time of waves I, III and V, and
the intervals between them, were measured.
Statistical analysis
Statistical analysis was performed using SigmaStat for
Windows Version 3.5 (Systat Software Inc., San Jose,
CA, USA). Data from the diabetic and control groups
was compared using an unpaired Student’s t-test, after
performing a Kolmogorov-Smirnov normality test and
a constant variance test. In the case of normality and/or
constant variance test failure, the Mann-Whitney rank
sum test was performed. The linear correlations be-
tween hearing function and age, diabetes duration,
HbA1C, and UAE in diabetic subjects were analysed us-
ing a Pearson product moment correlation test. In cas-
es of normality and/or constant variance test failure,
a Spearman rank order correlation test was performed.
To assess the strength and independency of associations,
a multiple linear regression test was used. A p value
< 0.05 was considered statistically significant.
Results
Pure-tone audiometry
Data from the air-conduction hearing thresholds of both
ears at each frequency was used in the analysis. In the
study group, 25 patients had normal hearing, five had
mild hearing loss, and one had moderate hearing loss.
In the control group, 23 subjects had normal hearing,
and three had mild hearing loss. In the diabetic group,
the mean hearing thresholds at frequencies 3,000–12,000
Hz were significantly higher compared to the control
group (Table I, Fig. 1).
In the diabetic group, in univariate analysis, the hear-
ing threshold showed a highly significant positive lin-
ear correlation with age at frequencies 2,000–12,000 Hz.
In multivariate analysis, after adjustment for diabetes
duration, HbA1C level and UAE, the correlation between
age and hearing threshold remained significant at fre-
quencies 3,000–12,000 Hz (Table II).
Transient evoked otoacoustic emissions
The otoacoustic emissions in the diabetic group were
absent bilaterally in six, and unilaterally in two, patients.
In the control group, they were absent bilaterally in two
and unilaterally in one subject. The mean amplitude of
TEOAE at band range 1.2–3.5 kHz was significantly low-
er in the study group compared to the control group.
Also at 1.5, 2 and 4 kHz the TEOAE response was sig-
nificantly lower in diabetic patients (Table III, Fig. 2).
In the diabetic patients, in univariate analysis, the
mean amplitude of TEOAE showed a negative linear
correlation with age (correlation coefficient R = –0.353,
Table I. Hearing thresholds in pure-tone audiometry
Tabela I. Próg słuchu w audiometrii tonalnej progowej
Frequency Hearing threshold p value
(Hz) (dB) (mean ± SD)
Diabetes Control
125 10.16 ± 1.27 10.00 ± 0.00 NS*
250 10.16 ± 1.27 10.00 ± 0.00 NS
500 10.24 ± 1.41 10.00 ± 0.00 NS
1,000 10.65 ± 3.07 10.00 ± 0.00 NS
2,000 10.57 ± 2.38 10.00 ± 0.00 NS (0.065)
3,000 12.18 ± 6.38 10.00 ± 0.00 0.003
4,000 13.47 ± 8.90  10.10 ± 0.69 0.002
6,000 13.95 ± 8.26 10.87 ± 3.39 0.004
8,000 13.47 ± 8.76 10.77 ± 2.87 0.013
12,000 15.32 ± 10.59 11.63 ± 4.61 0.018
*NS = non significant
Figure 1. Hearing threshold in pure-tone audiometry (mean ± SD);
diabetes – solid line and open squares; control – interrupted line
and solid triangles; *p < 0.05; ‡p < 0.005
Rycina 1. Próg słuchu w audiometrii tonalnej progowej (średnia ±
± SD); cukrzyca — linia ciągła i puste kwadraty, kontrola —
linia przerywana i pełne trójkąty; *p < 0,05, ‡p < 0,005
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p = 0.005). In multivariate analysis, the impact of age
on TEOAE amplitude appeared to be independent of
diabetes duration, metabolic control or UAE.
Nine of the diabetic patients (29.0%) achieved HbA1C
< 7%. In this group, the mean TEOAE amplitude was
higher in comparison with the remaining 22 patients
with lesser metabolic control (9.96 ± 4.58 dB v. 6.85 ±
± 4.09 dB, p = 0.011). However, no linear correlation
was found between HbA1C level and TEOAE amplitude.
Auditory brainstem responses
In the diabetic group, the latency time of wave V and
interval I–V duration was significantly longer compared
to the control group (5.78 ± 0.25 ms v. 5.69 ± 0.18 ms,
p = 0.025 and 4.03 ± 0.20 ms v. 3.95 ± 0.17 ms, p = 0.017
respectively). The interval I–III was also prolonged
in the study group (2.17 ± 0.15 ms v. 2.12 ± 0.18 ms),
but did not reach statistical significance (p = 0.059)
(Table IV, Fig. 3).
In the diabetic patients, in univariate analysis, we
found a negative linear correlation between diabetes
duration and latency time of wave V (R = –0.256, p = 0.045)
as well as interval I–V (R = –0.382, p = 0.004) (Fig. 4).
In multivariate analysis, the impact of diabetes dura-
tion on wave V and interval I–V latency was indepen-
dent of age, HbA1C level and UAE.
When diabetic patients were split into two sub-
groups according to diabetes duration (more or less than
five years), the 17 patients with a shorter history of dia-
betes demonstrated longer latency time of wave V (5.84
± 0.24 v. 5.70 ± 0.24 ms, p = 0.023), and also longer
intervals I–III (2.21 ± 0.14 ms v. 2.12 ± 0.15 ms,
p = 0.026) and I–V (4.08 ± 0.18 ms v. 3.97 ± 0.21 ms,
p = 0.030), compared to the 14 patients with a longer
diabetes history.
Retinopathy
Early background retinopathy was found in three dia-
betic patients. Despite this very small number, the
patients with retinopathy appeared to have signifi-
cantly higher hearing threshold in pure tone audio-
metry at 1, 2 and 4 kHz. No relationship between re-
tinopathy and otoacoustic emissions or ABR was
demonstrated.
Table II. Linear correlation between age and hearing
threshold at particular frequencies
Tabela II. Korelacja liniowa pomiędzy wiekiem a progiem
słuchu w poszczególnych częstotliwościach
Frequency Correlation p value Adjusted
(Hz)  coefficient R   p value*
125 0.050 NS† NS
250 0.050 NS NS
500 0.181 NS NS
1,000 –0.105 NS NS
2,000 0.259 0.043 NS (0.076)
3,000 0.442 < 0.001 < 0.001
4,000 0.564 < 0.001 < 0.001
6,000 0.545 < 0.001 < 0.001
8,000 0.587 < 0.001 < 0.001
12,000 0.475 < 0.001 0.002
*Adjusted for diabetes duration, HbA1C level and urinary albumin
excretion; †NS — non significant
Figure 2. Mean amplitude of TEOAE at band range 1.2–3.5 kHz
(bars) and at particular frequencies of TEOAE spectrum (presented
as TE-gram) (mean ± SD); diabetes – solid line and open squares;
control – interrupted line and solid triangles; *p < 0.05; ‡p <
0.005; §p < 0.001
Rycina 2. Uśredniona amplituda emisji otoakustycznej w zakresie
1.2–3.5 kHz (słupki) oraz w poszczególnych zakresach widma
TEOAE (przedstawiona jako TE-gram) (średnia ± SD); cukrzyca
— linia ciągła i puste kwadraty, kontrola — linia przerywana
i pełne trójkąty; *p < 0,05, ‡p < 0,005, §p < 0,001
Table III. Transient evoked otoacoustic emissions (TEOAE)
in diabetic and control groups
Tabela III. Emisja otoakustyczna wywołana trzaskiem
(TEOAE) u osób z cukrzycą i w grupie kontrolnej
Band (kHz) TEOAE amplitude p value
(dB) (mean ± SD)
Diabetes Control
1.2 – 3.5 7.75 ± 4.43 10.00 ± 4.01 < 0.001
1 3.67 ± 4.02 4.81 ± 4.74 NS*
1.5 7.12 ± 5.49 10.57 ± 5.77 0.002
2 7.21 ± 4.75 10.73 ± 4.81 < 0.001
3 7.18 ± 5.16 8.16 ± 4.05 NS
4 4.75 ± 3.79 6.45 ± 3.08 0.017
*NS — non significant
142
Auditory organ involvement in type 1 diabetes Mariusz Dąbrowski et al.
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
Discussion
Our study confirmed the existence of auditory organ
dysfunction in relatively young type 1 diabetic patients,
with a short duration of the disease and without clini-
cally overt hearing impairment. Significant differences
between diabetic and control groups were found in all
audiological tests.
The hearing threshold in the pure-tone audiometry
was in our study significantly higher at high and, par-
tially, middle frequencies in type 1 diabetic subjects in
comparison with healthy controls. Similar findings have
been revealed in other studies [2–8].
The amplitude of otoacoustic emissions in our ob-
servation was significantly lower in the diabetic patients
compared to the control group, which confirmed pre-
vious observations [9–12]. In one of those studies,
DPOAE (distortion product otoacoustic emissions),
which are more frequency-sensitive, rather than
TEOAE, were used [10]. Nevertheless, in all cases, OAE
were lower in the diabetic patients.
Auditory brainstem responses in our study showed
significant differences between diabetic and control
groups. The latency time of wave V and interval I–V in
diabetic patients were significantly longer compared to
healthy subjects. Other studies have also demonstrat-
ed prolonged wave V latency [9, 11, 13–15] and pro-
longed interval I–V duration [10, 13–15] in diabetic pa-
tients. Some of them have also found longer latency time
of wave I and wave III [9, 11, 15], as well as prolonged
intervals I–III [7, 15] and III–V [14].
The impact of age on hearing function is well docu-
mented. The hearing threshold increases, predominant-
ly at middle and high frequencies [19], whereas ampli-
tude of OAE decreases, with age [20]. Thus, unsurpris-
ingly, our study found a strong positive correlation be-
tween age and hearing threshold, as well as a negative
correlation between age and TEOAE in the diabetic
group. A similar impact of age on hearing threshold was
revealed in the study by Pudar et al. [8].
In the same study, differences regarding gender in
pure-tone audiometry (i.e. a higher threshold in men)
and in ABR (i.e. a shorter latency of wave III and V, as
Table IV. Auditory brainstem responses in the diabetic and
control groups
Tabela IV. Słuchowe potencjały wywołane pnia mózgu (ABR)
u osób z cukrzycą i w grupie kontrolnej
Parameter Time (ms) (mean ± SD) p value
Diabetes Control
Latency time
Wave I 1.73 ± 0.12 1.73 ± 0.11 NS*
Wave III 3.91 ± 0.19 3.86 ± 0.16 NS
Wave V 5.78 ± 0.25 5.69 ± 0.18 0.025
Interval duration
I–III 2.17 ± 0.15 2.12 ± 0.18 NS (0.059)
III–V 1.85 ± 0.16 1.83 ± 0.17 NS
I–V 4.03 ± 0.20 3.95 ± 0.17 0.017
*NS — non significant
Figure 3. Latencies and interval times in ABR (line: median; box:
25th and 75th percentile; error bars: 10th and 90th percentile; dots:
outliers) (the interval III – V is omitted); *p < 0.05
Rycina 3. Czasy latencji poszczególnych fal i interwałów pomiędzy
nimi (linia: mediana, ramka: 25 i 75 centyl, słupki błędów:
10 i 90 centyl, kropki: wartości odstające) (intervał III — V pominięto),
*p < 0,05
Figure 4. Negative linear correlation between diabetes duration
and latency time of wave V (solid circles, R = –0.256, p = 0.045)
and interval I–V (open circles, R = –0.382, p = 0.004) (scatter
plot and regression line)
Rycina 4. Ujemna korelacja liniowa pomiędzy czasem latencji
fali V (pełne kółka, R = –0,256, p = 0,045) oraz interwału I–V (puste
kółka, R = –0,382, p = 0,004) (wykres punktowy i linia regresji)
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well as longer I-III interval in women) were found.
However, it was not observed in the control group [8].
Since most previous studies comparing males and fe-
males with diabetes have found no sex differences in
audiological tests [6, 21, 22], we didn’t try to strictly
match the two groups regarding gender.
In our study, diabetes duration appeared to have
no impact on hearing threshold in diabetic patients. This
is contrary to other observations [2, 3, 5–8], which have
found a higher hearing threshold in longer lasting dia-
betes. The amplitude of OAE, neither in our study, nor
in others [9, 11] has shown an association with the dura-
tion of diabetes. One paper noted a correlation between
diabetes duration and prolongation of interval I–III [8],
and another found prolongation of latency time of wave
V and intervals I–V and III–V [14]. However, this has not
been observed in other studies [9, 11, 13, 15]. Interesting-
ly, in our study, wave V latency and interval I–V time
were inversely correlated with diabetes duration.
Metabolic control is a well-known risk factor for di-
abetic complications [23]. In our study, patients with
near-normal glycaemic control (HbA1C < 7%) demon-
strated higher TEOAE amplitude than subjects with
lesser glycaemic control. However, no linear correlation
between HbA1C level and TEOAE amplitude was found.
In other studies, an association between metabolic con-
trol and TEOAE amplitude was not revealed [9, 11]. We
didn’t find a relationship between metabolic control and
hearing threshold, or ABR results. Most other studies
also failed to find such a correlation [9, 11, 13, 14]. How-
ever, two studies showed a correlation between poor
metabolic control and higher hearing threshold [6, 7],
as well as with prolonged interval I-III in ABR [7]. An
interesting finding by Virtaniemi et al. was that ABR
disturbances did not reverse, even when an improve-
ment in metabolic control was achieved [24].
The association between hearing impairment and
other diabetic complications has been described in sev-
eral papers [11, 12, 14, 25]. Our study revealed a higher
hearing threshold at middle frequencies in patients with
retinopathy. Due to the fact that only one patient had
microalbuminuria, and none had clinically overt neur-
opathy, we did not analyse the relationship between
these complications and audiological test results.
Some discrepancies between the results of our study
and the studies mentioned above can be explained by
the fact that those studies used a different methodolo-
gy, as well as different inclusion/exclusion criteria, and
also studied highly heterogeneous populations.
Auditory organ involvement is present not only in
patients with type 1 diabetes, but also in type 2 diabetic
subjects. Among a population drawn from the National
Health and Nutrition Examination Survey (NHANES),
hearing impairment was more prevalent in adult dia-
betic subjects than in those without diabetes. This asso-
ciation was independent of known risk factors for hear-
ing loss, such as noise exposure, ototoxic medication
use, or smoking [26, 27]. Among veterans with type 2
diabetes, elevated hearing threshold and prolonged la-
tencies of wave V and interval I-V were observed, es-
pecially in younger patients (below 50 years), treated
with insulin, and presenting other diabetic complica-
tions [28, 29]. NHANES also revealed that over the last
30 years, the prevalence of hearing impairment has de-
creased significantly in the non-diabetic adult popula-
tion of the USA. However, this has not been replicated
in subjects with diabetes, where prevalence has re-
mained at the same level [30]. On the basis of the paper
by Bainbridge et al. [26], Hirose drew the conclusion
that audiometry should be considered as a routine eval-
uation in an annual test battery for diabetic patients [31].
The mechanisms involved in the development of
hearing dysfunction in diabetic patients are not so well
recognised as in the retina or in the kidney, primarily
due to the fact that they cannot be assessed by intravi-
tal examination. Few histopathological studies have
been carried out in humans. One such study found
microangiopathic changes in the vessels of stria vascu-
laris, the endolymphatic sac and the basilar membrane
of the cochlea [32]. Another study found thickening of
the capillary walls in the stria vascularis and in the basi-
lar membrane [33]. In addition, a greater loss of the outer
hair cells (OHC), predominantly in the lower basal turn
of the cochlea, and atrophy of the stria vascularis in di-
abetic subjects were also demonstrated. Since the basal
turn of the cochlea (where the microangiopathic chang-
es were predominantly seen) is responsible for receiv-
ing high frequencies [34], these findings could explain
the higher hearing threshold in diabetic patients at these
frequencies. The lower amplitude of OAE observed in
diabetic subjects can also be, at least in part, explained
by a greater OHC loss in this group.
The delay of auditory brainstem evoked potentials
observed in our study could be a manifestation of acous-
tic nerve and central auditory pathway neuropathy, as
it is seen in the peripheral nerves [35]. The relationship
between ABR disturbances and cardiac autonomic neu-
ropathy as well as peripheral neuropathy has been de-
scribed by Várkonyi et al. [36, 37]. The negative correla-
tion between diabetes duration and latency time of
wave V and interval I–V revealed in our work can be
potentially explained by nervous tissue metabolism,
where glucose is an essential nutrient. Chronic hyperg-
lycaemia in long lasting diabetes can induce adaptation-
al changes towards normalisation of intracellular me-
tabolism, and thus the tendency to normalisation of
conduction velocity, something speculated as regards
the retina by Klemp et al. in their paper [38].
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Conclusions
Although the study was performed on a small number
of participants, our results demonstrated that a relation-
ship between type 1 diabetes mellitus and auditory or-
gan dysfunction exists. Both the cochlear and the retro-
cochlear part of the auditory pathway, up to brainstem
level, are involved. Although the abnormalities were
subtle, they were statistically significant, and they were
detected before development of other diabetic microvas-
cular complications. It is worth noting that in our study,
elevated hearing threshold was also present at speech
frequency. Since hearing impairment may well have a
negative impact on the social function of an affected
individual, the use of audiological tests to monitor dia-
betic patients may be considered as a routine procedure,
in the same way as eye fundus examination and mi-
croalbuminuria assessment are.
However, the prognostic and predictive value of
auditory organ dysfunction, as well as methods of pos-
sible prevention of hearing loss, require further prospec-
tive observations to be properly determined.
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